Alzheimer's drug fails to reduce significant agitation

Thursday, May 3rd, 2012

A drug prescribed for Alzheimer's disease does not ease clinically significant agitation in patients, according to first randomized controlled trial designed to assess the effectiveness of the drug (generic name memantine) for significant agitation in Alzheimer's patients.

View post:
Alzheimer's drug ... continue reading

Alzheimer’s Disease Drug Developed At Roskamp Institute Approved For Key Clinical Trial Funding In Europe

Sunday, May 29th, 2011

An international research consortium led by Trinity College Dublin (Ireland) today announced the selection for funding of a large-scale European clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute in Sarasota. More than 500 Alzheimer’s patients will participate in the multicenter Phase III clinical trial designed ... continue reading